To the full analysis
IRadimed stock: valuation and P/E
IRMDIRadimed trades at a P/E of 45.8 (Medical (Devices) median 29.1, own median of recent years 35.5).
Daily figure as of 13 Nov 2026
P/E
45.8
P/S
12.2
P/B
10.31
PEG
4.13
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
45.8
Median of prior years
35.5
Reading
pricier than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 16.6 |
| 2017 | 303 |
| 2018 | 47 |
| 2019 | 27.5 |
| 2020 | 207.3 |
| 2021 | 60.8 |
| 2022 | 27.7 |
| 2023 | 34.9 |
| 2024 | 36.2 |
| 2025 | 55 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.